Folotyn Side Effects

Generic name: pralatrexate

Medically reviewed by Drugs.com. Last updated on Sep 21, 2024.

Note: This document provides detailed information about Folotyn Side Effects associated with pralatrexate. Some dosage forms listed on this page may not apply specifically to the brand name Folotyn.

Applies to pralatrexate: intravenous solution.

Serious side effects of Folotyn

Along with its needed effects, pralatrexate (the active ingredient contained in Folotyn) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking pralatrexate:

More common side effects

• black, tarry stools
• bleeding gums
• blood in the urine or stools
• body aches or pain
• chills
• convulsions
• cough
• cracked lips
• decreased urine
• diarrhea
• difficult or labored breathing
• difficulty with swallowing
• dry mouth
• ear congestion
• fast, pounding, or irregular heartbeat or pulse
• fever
• headache
• increased thirst
• loss of appetite
• loss of voice
• lower back or side pain
• mood changes
• muscle pain or cramps
• nasal congestion
• nausea or vomiting
• numbness or tingling in the hands, feet, or lips
• painful or difficult urination
• pale skin
• pinpoint red spots on the skin
• runny nose
• shortness of breath
• sneezing
• sore throat
• sores, ulcers, or white spots on the lips, tongue, or inside the mouth
• swelling
• tightness in the chest
• troubled breathing with exertion
• unusual bleeding or bruising
• unusual tiredness or weakness

Other side effects of Folotyn

Some side effects of pralatrexate may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• abdominal or stomach pain
• back pain
• bloody nose
• constipation
• itching skin
• lack or loss of strength
• night sweats
• pain in the arms or legs
• rash
• weight loss

For healthcare professionals

Applies to pralatrexate: intravenous solution.

General adverse events

The most common side effects observed in patients with peripheral T-cell lymphoma (PTCL) were mucositis, thrombocytopenia, nausea, and fatigue.^[Ref]

Hematologic

• Very common (10% or more): Thrombocytopenia (41%), anemia (34%), neutropenia (24%), leukopenia (11%)
• Common (1% to 10%): Febrile neutropenia, pancytopenia^[Ref]

Gastrointestinal

• Very common (10% or more): Mucositis (70%), nausea (40%), constipation (33%), vomiting (25%), diarrhea (21%), anorexia (15%)^[Ref]

Cardiovascular

• Very common (10% or more): Edema (30%), tachycardia (10%)
• Uncommon (0.1% to 1%): Cardiopulmonary arrest^[Ref]

Respiratory

• Very common (10% or more): Cough (28%), epistaxis (26%), dyspnea (19%), upper respiratory tract infection (10%)

Metabolic

• Very common (10% or more): Hypokalemia (15%)
• Common (1% to 10%): Dehydration

Dermatologic

• Very common (10% or more): Rash (15%), pruritus (14%)
• Frequency not reported: Skin exfoliation, ulceration, toxic epidermal necrolysis

Other

• Very common (10% or more): Fatigue (36%), pyrexia (32%), pharyngolaryngeal pain (14%), abdominal pain (12%), pain in extremity (12%), back pain (11%), night sweats (11%), asthenia (10%)

Hepatic

• Very common (10% or more): Abnormal liver function tests (13%)

Immunologic

• Common (1% to 10%): Sepsis

Further information

Folotyn side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer